Boston Scientific/ASTI deal targets bifurcated vessels
This article was originally published in The Gray Sheet
Executive Summary
Purchase of Advanced Stent Technologies, Inc. Dec. 16 will allow Boston Scientific to combine its Taxus paclitaxel-eluting stent technology with ASTI's Petal bifurcation coronary stent design to treat disease in bifurcated vessels, Boston Scientific says. Bifurcated lesions are present in as many as 30% of diseased vessels. A bare-metal Petal has FDA trial go-ahead (1"The Gray Sheet" Sept. 13, 2004, In Brief)...